Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 12/20 | 0.45 |
| ▸ | BRAF | P15056 | 7/20 | 0.45 |
| ▸ | CDK8 | P49336 | 3/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25420133 | 0.88 | CDK8 (0.53) | RAF1MAPK3KDRBRAFCDK8 | |
| SCHEMBL29536535 | 0.88 | CDK8 (0.53) | RAF1MAPK3KDRBRAFCDK8 | |
| SCHEMBL26075423 | 0.88 | RAF1 (0.48) | RAF1MAPK3KDRBRAFCDK8 | |
| SCHEMBL26075468 | 0.81 | MET (0.48) | KDRRET | |
| SCHEMBL26074904 | 0.79 | CDK8 (0.61) | RAF1MAPK3KDRBRAFCDK8 | |
| SCHEMBL29537632 | 0.74 | MET (0.34) | KDRRET | |
| SCHEMBL25421713 | 0.73 | MET (0.37) | RAF1MAPK3KDRBRAF | |
| SCHEMBL26074902 | 0.73 | EPHX2 (0.44) | CDK8CCNC | |
| SCHEMBL29536773 | 0.73 | EPHX2 (0.44) | CDK8CCNC | |
| SCHEMBL25420084 | 0.72 | PDE4B (0.40) | KDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | RAF1 115/4885MAPK3 79/4885KDR 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.